Clinical Trial Update: A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults [Phase 3]

View source ↗

Summary

Phase 3 trial update for mRNA-1345 vaccine targeting respiratory syncytial virus (RSV) in high-risk adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• mRNA-1345

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Respiratory Syncytial Virus | Phase 3 | Status: COMPLETED